FDA Approves Geron’s Lytero for Treatment of Adults with Low-Risk Myelodysplastic Syndrome

If approved, Rytelo could potentially enable patients with low-risk myelodysplastic syndromes to receive treatment for extended periods without needing red blood cell transfusions to relieve symptomatic anemia.